natgillin/translations-raw huggingface dataset:
After reconstitution each ml contains 10 mg of micafungin (as sodium).
Pärast lahustamist sisaldab üks milliliiter 10 mg mikafungiini (naatriummikafungiinina).
Metabolism and nutritional disorders hypokalaemia, hypomagnesaemia, hypocalcaemia hyponatraemia, hyperkalaemia, hypophosphataemia, anorexia
Ainevahetus- ja toitumishäired hüpokaleemia, hüpomagneseemia,
(hypomagnesaemia); decreased calcium in the blood (hypocalcaemia) - headache - inflammation of the vein wall (at injection-site) - nausea (feeling sick); vomiting (being sick); diarrhoea; abdominal pain - abnormal liver function tests (increased alkaline phosphatase; increased aspartate aminotransferase, increased alanine aminotransferase) - increased bile pigment in the blood (hyperbilirubinaemia) - rash - fever - rigors (shivering)
ikterus (maksa- või vereprobleemide tõttu tekkinud naha või silmavalgete kollasus), soolde jõudva sapi hulga vähenemine (kolestaas), maksa suurenemine, maksapõletik - sügelev lööve (urtikaaria), sügelemine, nahapunetus (erüteem) - normist kõrvalekalletega neerufunktsiooni testid (kreatiniini sisalduse suurenemine veres, uurea sisalduse suurenemine veres), neerupuudulikkuse süvenemine - laktaatdehüdrogenaasi nimelise ensüümi aktiivsuse suurenemine - vere hüübimine süstekoha veenis, põletik süstekohas, valu süstekohas, vedeliku kogunemine kehas
Each vial contains: 50 mg micafungin (as sodium).
Üks viaal sisaldab: 50 mg mikafungiini (naatriummikafungiinina).
Cardiac disorders common tachycardia
Südame häired sage tahhükardia
An intact cell wall is necessary for the fungus to continue living and growing.
Seene eluks ja kasvuks on vajalik terve rakusein.
Although a possible effect in decreasing gingivitis was observed, information on how the study was conducted is incomplete, so firm conclusions could not be drawn.
Kuigi täheldati võimalikku mõju gingiviidi vähenemisele, ei olnud piisavalt teavet, kuidas uuring läbi viidi ja ei saa teha kindlaid järeldusi.
31 May 2016 EMA/270540/2016
EMA/270540/2016
Knotgrass herb medicines should only be used in adults and adolescents over the age of 12 years.
Linnurohuürti sisaldavaid ravimeid tohivad kasutada üksnes täiskasvanud ja vähemalt 12 aasta vanused noorukid.
Knotgrass herb EMA/270540/2016
Linnurohuürt EMA/270540/2016
Further information on the risks associated with knotgrass herb medicines, including the appropriate precautions for their safe use can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Lisateave linnurohuürti sisaldavate ravimitega kaasnevate riskide, sh nende ohutu kasutamise ettevaatusabinõude kohta, on taimse aine monograafias Euroopa Ravimiameti veebilehe jaotises „All documents“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Further information on the HMPC assessment of knotgrass herb medicines, including details of the Committee's conclusions can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Lisateave linnurohuürti sisaldavate ravimite hindamise kohta, sh komitee kokkuvõtte üksikasjalik kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Any applications for the licensing of medicines containing knotgrass herb have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Linnurohuürti sisaldavate ravimite müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimsete ravimite müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslikke järeldusi.
Detailed instructions on how to take knotgrass herb medicines and who can use them can be found in the package leaflet that comes with the medicine.
Üksikasjalik teave, kuidas võtta linnurohuürti sisaldavaid ravimeid ja kes neid tohib kasutada, on ravimi pakendi infolehel.
In its assessment, the HMPC considered a clinical study in men with gingivitis (inflammation of the gum).
Taimsete ravimite komitee uuris hinnangu andmisel ka kliinilist uuringut gingiviidiga (igemepõletikuga) meestel.
Information on the use and licensing of knotgrass herb medicines in EU Member States should be obtained from the relevant national authorities.
ELi liikmesriikides saab linnurohuürti sisaldavate ravimite kasutamise ja müügilubade teavet asjakohastelt riiklikelt ravimiametitelt.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing knotgrass herb.
ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad linnurohuürti sisaldavate taimsete ravimite müügilubade taotlusi.
However, because of the limitations with the available data, the HMPC conclusions on the use of these knotgrass herb medicines are based on their long-standing use.
Kuid kuna saada on ainult piiratud andmed, põhineb taimsete ravimite komitee järeldus linnurohuürti sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
Knotgrass herb preparations may also be found in combination with other herbal substances in some herbal medicines.
Mõnes taimses ravimis võib esineda linnurohuürdi valmistisi ka kombinatsioonis teiste taimsete ainetega.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of knotgrass herb.
See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb linnurohuürdi meditsiinilisi kasutusviise.
This summary is not intended to provide practical advice on how to use medicines containing knotgrass herb.
Kokkuvõttes ei anta linnurohuürti sisaldavate ravimite kasutamise praktilisi nõuandeid.
The HMPC concluded, that on the basis of its long-standing use, these knotgrass herb preparations can be used for the relief of symptoms of common cold, for treating symptoms of minor mouth or throat inflammation and for minor problems affecting the urinary tract (structures that carry urine) to increase the production of urine in order to achieve flushing of the urinary tract.
Taimsete ravimite komitee järeldas, et lähtudes pikaajalisest kasutamisest tohib seda linnurohuürdi valmistist kasutada külmetuse sümptomite, kergete suu või kurgu põletiku sümptomite ja kergete kuseteede probleemide (et suurendada uriini tootmist ja saavutada kuseteid loputav toime) leevendamiseks.
If symptoms last longer than two weeks or worsen during the use of the medicine for minor urinary tract problems a doctor or qualified healthcare practitioner should be consulted.
kasutamise ajal kauem kui kaks nädalat või halvenevad selle aja jooksul, tuleb konsulteerida arsti või pädeva tervishoiuteenuse osutajaga.
The HMPC also considered studies in laboratory tests which support anti-inflammatory and antibacterial effects of knotgrass herb medicines.
Taimsete ravimite komitee uuris hinnangu andmisel ka laborikatseid, mis toetavad linnurohuürdi põletikuvastast ja bakterivastast toimet.
The HMPC conclusions on the use of these knotgrass herb medicines for common colds, minor mouth or throat inflammation and minor problems affecting the urinary tract are based on their ‘traditional use'.
Taimsete ravimite komitee järeldused nende linnurohuürti sisaldavate ravimite kasutamise kohta külmetuse, kergete suu või kurgu põletike ja kergete kuseteede probleemide leevendamiseks põhinevad nende traditsioonilisel kasutamisel.
Herbal medicines containing these knotgrass herb preparations are usually available as herbal material that is used to make herbal teas to be drunk or added to water to produce a liquid (decoction) to be applied to the lining of the mouth.
Taimsed ravimid, mis sisaldavad linnurohuürdi valmistisi, turustatakse tavaliselt taimeteena, mida juuakse või mida lisatakse vette, et saada vedelik, mida manustatakse suu limaskestale.
If symptoms last longer than one week or worsen during the use of the medicine for common cold symptoms or for minor mouth or throat inflammation, a doctor or qualified healthcare practitioner
Kui külmetuse või kerge suu või kurgu põletiku sümptomid kestavad ravimi kasutamise ajal kauem kui ühe nädala või halvenevad selle aja jooksul, tuleb konsulteerida arsti või pädeva tervishoiuteenuse osutajaga.
For more information about treatment with knotgrass herb medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Kui vajate linnurohuürti sisaldavate ravimitega toimuva ravi kohta lisateavet, lugege palun ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
What is knotgrass herb?
Mis on linnurohuürt?
What evidence supports the use of knotgrass herb medicines?
Mis tõendid toetavad linnurohuürti sisaldavate ravimite kasutamist?
What are the risks associated with knotgrass herb medicines?
Mis riskid linnurohuürti sisaldavate ravimitega kaasnevad?
For practical information about using knotgrass herb medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Kui vajate linnurohuürti sisaldavate ravimite kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
Other information about knotgrass herb medicines
Muu teave linnurohuürti sisaldavate ravimite kohta
How are knotgrass herb medicines approved in the EU?
Kuidas antakse Euroopa Liidus linnurohuürti sisaldavate ravimite müügiluba?
What are the HMPC conclusions on its medicinal uses?
Mis on taimsete ravimite komitee järeldused linnurohuürdi meditsiiniliste kasutusalade kohta?
Knotgrass herb is the common name for the flowering aerial parts of the plant Polygonum aviculare L. The HMPC conclusions only cover knotgrass herb preparations which are obtained by drying and comminuting (reducing into tiny pieces) the flowering aerial parts.
Linnurohuürt on taime Polygonum aviculare L. maapealsete õitsvate osade üldnimetus.
Neupro is applied once a day at about the same time every day.
Neuprot kasutatakse üks kord ööpäevas, iga päev ligikaudu samal ajal.
Neupro rotigotine
Neupro rotigotiin
Neupro is used when a specific cause for the disorder cannot be identified.
Neuprot kasutatakse, kui selle häire konkreetset põhjust ei ole võimalik kindlaks määrata.
The European Commission granted a marketing authorisation valid throughout the European Union for Neupro on 15 February 2006.
Euroopa Komisjon andis Neupro müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. veebruaril
The full EPAR for Neupro can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Euroopa avaliku hindamisaruande täistekst Neupro kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Neupro
Muu teave Neupro kohta
Neupro is used to treat the symptoms of the following diseases in adults:
Neuprot kasutatakse järgmiste haiguste sümptomite ravimiseks täiskasvanutel:
The backing layer of Neupro contains aluminium.
Neupro aluskiht sisaldab alumiiniumi.
The CHMP decided that Neupro's benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Neupro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
This is a summary of the European public assessment report (EPAR) for Neupro.
See on ravimi Neupro Euroopa avaliku hindamisaruande kokkuvõte.
What is Neupro?
Mis on Neupro?
In the smaller studies completed later, the effectiveness of Neupro was found to be comparable with ropinirole.
Hiljem tehtud väiksemates uuringutes oli Neupro efektiivsus võrreldav ropinirooli efektiivsusega.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Neupro.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
For more information about treatment with Neupro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Neuproga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
The decrease seen with Neupro was similar to that seen with pramipexole (2.8 h).
Neuproga saavutatud vähenemine oli sarnane pramipeksooliga saavutatuga (2,8 h).
Neupro must not be used in people who are hypersensitive (allergic) to rotigotine or any of the other ingredients.
Neuprot ei tohi kasutada patsiendid, kes on rotigotiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Neupro was less effective than ropinirole: an improvement was seen in 70% of the patients receiving ropinirole.
Neupro oli ropiniroolist vähem efektiivne: ropinirooliga vähenesid sümptomid 70%-l patsientidest.
Neupro is used on its own in early-stage disease, or in combination with levodopa (another medicine used in Parkinson's disease) at any stage of the disease, including the later stages when levodopa starts becoming less effective;
Neuprot kasutatakse ainsa ravimina varases järgus Parkinsoni tõve raviks või koos levodopaga (samuti Parkinsoni tõve ravim) haiguse mis tahes järgus, sealhulgas hilisstaadiumis, mil levodopa efektiivsus hakkab vähenema;
Neupro was more effective than placebo in treating Parkinson's disease.
Neupro oli Parkinsoni tõve ravis efektiivsem kui platseebo.
Neupro delivers a constant supply of rotigotine through the skin into the bloodstream.
Neupro eraldab läbi naha vereringesse pidevalt rotigotiini.
Two of these studies also compared Neupro with other dopamine agonists (ropinirole in early-stage disease and pramipexole in advanced disease).
Neist kahes uuringus võrreldi Neuprot ka dopamiini teiste agonistidega (haiguse varajase järgu korral ropinirooliga ja hilise järgu korral pramipeksooliga).
In moderate to severe restless legs syndrome, Neupro has been compared with placebo in two main studies involving a total of 963 patients.
Rahutute jalgade mõõduka kuni raske sündroomi korral võrreldi Neuprot platseeboga kahes põhiuuringus, milles osales kokku 963 patsienti.
Why has Neupro been approved?
Miks Neupro heaks kiideti?
In Parkinson's disease, Neupro has been compared with placebo (a dummy treatment) in four studies involving 830 patients with early-stage disease and 842 patients with advanced disease.
Parkinsoni tõve ravis võrreldi Neuprot platseeboga (näiv ravim) neljas uuringus, milles osales 830 haiguse varajases ja 842 hilises järgus patsienti.
What is the risk associated with Neupro?
Mis riskid Neuproga kaasnevad?
For the full list of all side effects reported with Neupro, see the package leaflet.
Neupro kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
The most common side effects with Neupro in patients with Parkinson's disease (seen in more than 1 patient in 10) are somnolence (sleepiness), dizziness, headache, nausea (feeling sick), vomiting, and application site reactions such as redness, itching and irritation of the skin.
Parkinsoni tõvega patsientidel olid Neupro kasutamise kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) unisus, peapööritus, peavalu, iiveldus, oksendamine ja manustuskoha reaktsioonid, näiteks punetus, sügelus ja naha ärritus.
In early-stage disease, 48 to 52% of the patients using Neupro had an improvement in symptoms, compared with 19 to 30% of those using placebo.
Haiguse varajases järgus leevenesid sümptomid Neupro kasutamisel 48-52%-l patsientidest, platseebo kasutamisel aga 19-30%-l patsientidest.
Neupro is a range of transdermal patches (patches that deliver a medicine across the skin).
Neuprot turustatakse mitmesuguste transdermaalsete plaastritena (plaaster, millest ravim imbub organismi läbi naha).
To avoid skin burns, Neupro must be removed if the patient has to have magnetic resonance imaging (MRI) or cardioversion (a process that restores the heart's normal rhythm).
Kui patsiendile on vaja teha magnetresonantstomograafia (MRI) või kardioversioon (südame normaalse rütmi taastamise protseduur), tuleb Neupro nahapõletuste vältimiseks eemaldada.
The medicine can only be obtained with a prescription.
Neupro on retseptiravim.
The active substance in Neupro, rotigotine, is a dopamine agonist, which means that it imitates the action of dopamine.
Neupro toimeaine rotigotiin on dopamiini agonist, st sellel on dopamiiniga analoogne toime.
What benefit has Neupro shown during the studies?
Milles seisneb uuringute põhjal Neupro kasulikkus?
In advanced Parkinson's disease, patients using Neupro had a greater decrease in their ‘off' time than those taking placebo (a decrease of 2.1 to 2.7 h with Neupro compared with 0.9 h with placebo).
Haiguse hilises järgus Neuprot kasutanud patsientidel vähenes passiivses seisundi kestus rohkem kui platseebot saanud patsientidel (Neuproga 2,1-2,7 h ja platseeboga 0,9 h).
In restless legs syndrome, patients using doses of Neupro between 1 and 3 mg/24 h had a greater improvement than those using placebo in the two studies, as measured on both symptom scales.
Rahutute jalgade sündroomi ravis paranesid Neuprot annuses 1 ja 3 mg/24 h võtnud patsientide näidud mõlemal sümptomite skaalal rohkem kui platseebot saanud patsientidel.
How does Neupro work?
Kuidas Neupro toimib?
How is Neupro used?
Kuidas Neuprot kasutatakse?
What is Neupro used for?
Milleks Neuprot kasutatakse?
Two smaller studies comparing Neupro with ropinirole were completed after the medicine's authorisation.
Pärast müügiloa saamist tehti kaks väiksemat uuringut, milles võrreldi Neuprot ropinirooliga.
How has Neupro been studied?
Kuidas Neuprot uuriti?
It is used in patients who are at risk of fractures (broken bones), including those who have recently broken their hip in a minor trauma such as a fall, and in patients whose osteoporosis is linked to long-term treatment with glucocorticoids (a type of steroid).
Seda kasutatakse patsientidel, kellel on luumurru risk, sealhulgas patsientidel, kellel on hiljuti saanud väikese trauma (nt kukkumise) tagajärjel puusamurru, samuti patsientidel, kelle osteoporoos on seotud pikaajalise glükokortikoidraviga (teatud steroidraviga).
The full EPAR for Zoledronic acid Teva Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst ravimi Zoledronic acid Teva Pharma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Using paracetamol or ibuprofen (anti-inflammatory medicines) shortly after Zoledronic acid Teva Pharma can reduce symptoms such as fever, muscle pain, influenza (flu)-like symptoms, joint pain and headache in the three days following the infusion.
Paratsetamooli või ibuprofeeni (põletikuvastased ravimid) kasutamine lühiajaliselt pärast ravimi Zoledronic acid Teva Pharma manustamist võib vähendada sümptomeid, nagu palavik, lihasevalu, gripilaadsed sümptomid, liigesevalu ja peavalu, infusioonile järgneva kolme ööpäeva jooksul.
A risk management plan has been developed to ensure that Zoledronic acid Teva Pharma is used as safely as possible.
Töötati välja riskijuhtimiskava, et tagada ravimi Zoledronic acid Teva Pharma võimalikult ohutu kasutamine.
The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Teva Pharma on 16 August 2012.
Euroopa Komisjon andis ravimi Zoledronic acid Teva Pharma müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. augustil 2012.
No additional studies were needed as Zoledronic acid Teva Pharma is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Aclasta.
Lisauuringuid ei olnud vaja, sest Zoledronic acid Teva Pharma on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Aclasta.
What measures are being taken to ensure the safe and effective use of Zoledronic acid Teva Pharma?
Mis meetmed võetakse, et tagada ravimi Zoledronic acid Teva Pharma ohutu ja efektiivne kasutamine?
The CHMP concluded that, in accordance with EU requirements, Zoledronic acid Teva Pharma has been shown to be comparable to Aclasta.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Zoledronic acid Teva Pharma võrreldavus ravimiga Aclasta.
For more information about treatment with Zoledronic acid Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate ravimiga Zoledronic acid Teva Pharma toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Teva Pharma.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
This means that Zoledronic acid Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aclasta.
See tähendab, et Zoledronic acid Teva Pharma on sarnane võrdlusravimiga Aclasta, millel juba on Euroopa Liidus müügiluba.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid Teva Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi Zoledronic acid Teva Pharma omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Zoledronic acid Teva Pharma is given as an infusion lasting at least 15 minutes.
Ravimit Zoledronic acid Teva Pharma manustatakse vähemalt 15 minutit kestva infusioonina.
Because Zoledronic acid Teva Pharma is a generic, its benefits and risks are taken as being the same as the reference medicine's.
Et Zoledronic acid Teva Pharma on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
Zoledronic acid Teva Pharma is a solution for infusion (drip) into a vein that contains the active substance zoledronic acid (5 mg).
Zoledronic acid Teva Pharma on infusioonilahus (veeni tilgutatav lahus), mis sisaldab toimeainena soledroonhapet (5 mg).
For Paget's disease, only one infusion of Zoledronic acid Teva Pharma is usually given, but additional infusions can be considered if the patient's disease comes back.
Pageti luuhaigusega patsientidele tehakse ainult üks Zoledronic acid Teva Pharma infusioon, kuid haiguse taastudes võib infusioone korrata.
In the treatment of Paget's disease of the bone, Zoledronic acid Teva Pharma must only be used by a doctor who has experience in the treatment of the disease.
Pageti luuhaiguse raviks tohib ravimit Zoledronic acid Teva Pharma manustada vaid selle haiguse ravis kogenud arst.
This is a summary of the European public assessment report (EPAR) for Zoledronic acid Teva Pharma.
See on ravimi Zoledronic acid Teva Pharma Euroopa avaliku hindamisaruande kokkuvõte.
Patients who have broken their hip should not receive Zoledronic acid Teva Pharma any earlier than two weeks after the operation to repair the fracture.
Puusamurruga patsiendid tohivad ravimit Zoledronic acid Teva Pharma kasutada alles kaks nädalat pärast puusamurru parandamise operatsiooni.
The Committee recommended that Zoledronic acid Teva Pharma be given marketing authorisation.
Komitee soovitas anda ravimi Zoledronic acid Teva Pharma müügiloa.
Other information about Zoledronic acid Teva Pharma
Muu teave ravimi Zoledronic acid Teva Pharma kohta
Zoledronic acid Teva Pharma is also used to treat Paget's disease of the bone in adults.
Ravimit Zoledronic acid Teva Pharma kasutatakse ka Pageti luutõve raviks täiskasvanutel.